Short description
Actym Therapeutics is a biotech company that focuses on the discovery and development of novel immuno-oncology therapies to treat cancer.
Description
Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy.
In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.
Last funding
Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Berkeley, California, United States, North America
Founded on
May 1, 2017
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noaccess, Nopepepe, Noaccess, Uh Ohhhh, Uh Ohhhh, Nopepepe, Uh Ohhhh
Sign in for full access
Founders
Amit Kumar, Christopher Thanos, Laura Hix Glickman